InSite Vision Announces Clinical Study of Novel Glaucoma Treatment
ALAMEDA, Calif.--(BW HealthWire)--Sept. 11, 1998--InSite Vision Inc. (AMEX:ISV - news) today announced it had started a Phase II study of ISV-205, its novel product candidate for the treatment of glaucoma.
In preclinical studies, ISV-205 inhibited the production of a protein that appears to block the outflow of fluids from the eye, resulting in elevated intraocular pressure (IOP) and optic nerve damage associated with glaucoma. The protein is the product of the recently discovered glaucoma-causing TIGR gene.
''We believe ISV-205 has the potential to be the first glaucoma drug that treats the cause of the disease instead of its symptoms,'' said Kumar Chandrasekaran, Ph.D., InSite Vision's Chairman and Chief Executive Officer. ''Our researchers have conducted extensive preclinical studies which indicate the drug may prevent the accumulation of the TIGR protein in the eye. This trial is designed to confirm its efficacy in humans.''
InSite Vision is an ophthalmic product development company with programs based on three platforms: genetic research for diagnosis and prognosis of glaucoma; the development of new and improved ophthalmic drugs using its proprietary DuraSite(R) eyedrop-based delivery system; and the non-surgical delivery of drugs to the back of the eye.
This press release contains, among other things, certain statements of a forward-looking nature relating to future events or the future business performance of InSite Vision. Such statements entail a number of risks and uncertainties involving the results of preclinical and clinical studies and determinations by the U.S. Food and Drug Administration, as well as the Risk Factors listed from time to time in the Company's SEC filings including, but not limited to, its Form 10Q for the quarter ended June 30, 1998.
biz.yahoo.com
|
